Telix Pharmaceuticals Ltd (TLPPF) — SEC Filings
Telix Pharmaceuticals Ltd (TLPPF) — 34 SEC filings. Latest: 6-K (Dec 22, 2025). Includes 33 6-K, 1 20-F.
View Telix Pharmaceuticals Ltd on SEC EDGAR
Overview
Telix Pharmaceuticals Ltd (TLPPF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 22, 2025: On December 22, 2025, Telix Pharmaceuticals Limited announced updates regarding its precision medicine portfolio. Key developments include the initiation of a Phase 3 study for Illuccix in China, and FDA resubmissions for TLX101-CDx and TLX250-CDx. These advancements are part of Telix's strategy to
Sentiment Summary
Across 34 filings, the sentiment breakdown is: 14 bullish, 20 neutral. The dominant filing sentiment for Telix Pharmaceuticals Ltd is neutral.
Filing Type Overview
Telix Pharmaceuticals Ltd (TLPPF) has filed 33 6-K, 1 20-F with the SEC between Nov 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (34)
Risk Profile
Risk Assessment: Of TLPPF's 33 recent filings, 0 were flagged as high-risk, 13 as medium-risk, and 20 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Anne Whitaker
Top Tags
pharmaceuticals (8) · foreign-issuer (7) · oncology (7) · regulatory-approval (5) · regulatory-update (4) · acquisition (4) · drug-development (3) · revenue-growth (3) · financial-results (3) · international-expansion (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Third Quarter Revenue | US$206M | Indicates strong sales performance for the period. |
| Q2 Revenue | US$240M | Represents a 63% year-over-year increase. |
| Year-over-Year Revenue Growth | 63% | Highlights significant commercial expansion. |
| Q1 2025 Revenue | US$186M | Represents a 62% increase year-over-year |
| Fiscal Year End | 2024 | The period covered by the 20-F filing. |
| Filing Date | 2025-02-24 | The date the 20-F was submitted to the SEC. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Telix Pharmaceuticals Ltd (TLPPF)?
Telix Pharmaceuticals Ltd has 34 recent SEC filings from Nov 2024 to Dec 2025, including 33 6-K, 1 20-F. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TLPPF filings?
Across 34 filings, the sentiment breakdown is: 14 bullish, 20 neutral. The dominant sentiment is neutral.
Where can I find Telix Pharmaceuticals Ltd SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Telix Pharmaceuticals Ltd (TLPPF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Telix Pharmaceuticals Ltd?
Financial highlights for Telix Pharmaceuticals Ltd are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for TLPPF?
Investment thesis data for TLPPF will be available once enriched filings are processed.
Who are the key executives at Telix Pharmaceuticals Ltd?
Key executives identified across Telix Pharmaceuticals Ltd's filings include Anne Whitaker.
What are the main risk factors for Telix Pharmaceuticals Ltd stock?
Of TLPPF's 33 assessed filings, 0 were flagged high-risk, 13 medium-risk, and 20 low-risk.
What are recent predictions and forward guidance from Telix Pharmaceuticals Ltd?
Forward guidance and predictions for Telix Pharmaceuticals Ltd are extracted from SEC filings as they are enriched.